U.S. health officials have approved a new generic version of EpiPen, the emergency allergy medication.
The Food and Drug Administration's action Thursday opens the door to more competition for a drug that has faced public outrage over its price tag. The injections are stocked by schools and parents to treat allergic reactions to food and bug bites.
[Ads /]
The new generic version will be sold by Teva Pharmaceuticals.
EpiPen maker Mylan has dominated the $1 billion market for two decades. Competing shots are not widely marketed or prescribed by doctors.
[Ads /]
In 2016, Congress blasted Mylan for raising the price to $600, a five-fold increase over nearly a decade. The company responded by launching its own lower-cost generic version for $300.